nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—ABCG2—Conjugated Estrogens—osteoporosis	0.0997	0.198	CbGbCtD
Leflunomide—ABCG2—Estradiol—osteoporosis	0.0876	0.174	CbGbCtD
Leflunomide—CYP1A2—Estropipate—osteoporosis	0.0869	0.173	CbGbCtD
Leflunomide—CYP2C9—Estropipate—osteoporosis	0.0783	0.156	CbGbCtD
Leflunomide—CYP1A2—Conjugated Estrogens—osteoporosis	0.0411	0.0818	CbGbCtD
Leflunomide—CYP2C9—Cholecalciferol—osteoporosis	0.0404	0.0803	CbGbCtD
Leflunomide—CYP1A2—Estradiol—osteoporosis	0.0361	0.0718	CbGbCtD
Leflunomide—CYP2C9—Estradiol—osteoporosis	0.0325	0.0647	CbGbCtD
Leflunomide—PTK2B—Interleukin-2 signaling—IL6R—osteoporosis	0.000711	0.00604	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—IRS2—osteoporosis	0.0007	0.00595	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PKM—osteoporosis	0.0007	0.00595	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—FDPS—osteoporosis	0.0007	0.00595	CbGpPWpGaD
Leflunomide—PTK2B—IL-7 Signaling Pathway—MYC—osteoporosis	0.000698	0.00594	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—RAP1A—osteoporosis	0.000697	0.00593	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—LEP—osteoporosis	0.000685	0.00582	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—IRS1—osteoporosis	0.000677	0.00576	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—GPD2—osteoporosis	0.000663	0.00564	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PGLS—osteoporosis	0.000663	0.00564	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—BMP2—osteoporosis	0.000646	0.00549	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—IRS1—osteoporosis	0.000611	0.00519	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—ATIC—osteoporosis	0.000607	0.00516	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PNP—osteoporosis	0.000607	0.00516	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—IRS1—osteoporosis	0.000599	0.00509	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IRAK3—osteoporosis	0.000589	0.00501	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—IRS1—osteoporosis	0.000584	0.00496	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—ESR1—osteoporosis	0.00058	0.00493	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—IGF1—osteoporosis	0.000566	0.00481	CbGpPWpGaD
Leflunomide—ABCG2—Fluoropyrimidine Activity—MTHFR—osteoporosis	0.000562	0.00478	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—IGF1—osteoporosis	0.000555	0.00472	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—IRS1—osteoporosis	0.000542	0.00461	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—ENO1—osteoporosis	0.000537	0.00457	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—OXCT1—osteoporosis	0.000516	0.00439	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—CA2—osteoporosis	0.000516	0.00439	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—MGLL—osteoporosis	0.000503	0.00427	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—LEP—osteoporosis	0.000483	0.00411	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—MYC—osteoporosis	0.000461	0.00392	CbGpPWpGaD
Leflunomide—CYP1A2—Estrogen Receptor Pathway—ESR1—osteoporosis	0.000454	0.00386	CbGpPWpGaD
Leflunomide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000446	0.00379	CbGpPWpGaD
Leflunomide—CYP2C9—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.00044	0.00374	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—IDH2—osteoporosis	0.000427	0.00363	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—CYP27A1—osteoporosis	0.000402	0.00342	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—SPP1—osteoporosis	0.000391	0.00333	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—ACP5—osteoporosis	0.000391	0.00332	CbGpPWpGaD
Leflunomide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000381	0.00324	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—MYC—osteoporosis	0.000377	0.00321	CbGpPWpGaD
Leflunomide—CYP1A2—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000376	0.0032	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—IL6R—osteoporosis	0.000368	0.00313	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—IL6R—osteoporosis	0.000365	0.00311	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—TPI1—osteoporosis	0.000363	0.00309	CbGpPWpGaD
Leflunomide—CYP2C9—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000361	0.00307	CbGpPWpGaD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—osteoporosis	0.000356	0.00303	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—IRS2—osteoporosis	0.000354	0.00301	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—IL6R—osteoporosis	0.000347	0.00295	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—P4HB—osteoporosis	0.000342	0.00291	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—TGFB1—osteoporosis	0.000339	0.00288	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—GAPDH—osteoporosis	0.000335	0.00285	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—RAP1A—osteoporosis	0.000327	0.00278	CbGpPWpGaD
Leflunomide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000322	0.00274	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—IL1B—osteoporosis	0.000322	0.00273	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—TNF—osteoporosis	0.000317	0.00269	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—IL6—osteoporosis	0.000317	0.00269	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—IRS1—osteoporosis	0.000309	0.00263	CbGpPWpGaD
Leflunomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000309	0.00263	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—MYC—osteoporosis	0.000302	0.00257	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—LEP—osteoporosis	0.000301	0.00256	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—IL1B—osteoporosis	0.000278	0.00236	CbGpPWpGaD
Leflunomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000276	0.00234	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—ENO1—osteoporosis	0.000264	0.00225	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PSMA5—osteoporosis	0.00026	0.00221	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PSMA2—osteoporosis	0.00026	0.00221	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—IL6—osteoporosis	0.000256	0.00217	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—TGFB1—osteoporosis	0.00025	0.00212	CbGpPWpGaD
Leflunomide—CYP1A2—Tryptophan metabolism—CYP19A1—osteoporosis	0.000248	0.0021	CbGpPWpGaD
Leflunomide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000234	0.00199	CbGpPWpGaD
Leflunomide—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000231	0.00197	CbGpPWpGaD
Leflunomide—CYP2C9—Arachidonic acid metabolism—GPX1—osteoporosis	0.000221	0.00188	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—CYP19A1—osteoporosis	0.000211	0.00179	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IRS2—osteoporosis	0.000208	0.00177	CbGpPWpGaD
Leflunomide—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000205	0.000539	CcSEcCtD
Leflunomide—Asthenia—Estropipate—osteoporosis	0.000204	0.000537	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—SOST—osteoporosis	0.000204	0.00173	CbGpPWpGaD
Leflunomide—Anorexia—Pamidronate—osteoporosis	0.000203	0.000536	CcSEcCtD
Leflunomide—Chest pain—Zoledronate—osteoporosis	0.000203	0.000536	CcSEcCtD
Leflunomide—Myalgia—Zoledronate—osteoporosis	0.000203	0.000536	CcSEcCtD
Leflunomide—Arthralgia—Zoledronate—osteoporosis	0.000203	0.000536	CcSEcCtD
Leflunomide—Palpitations—Conjugated Estrogens—osteoporosis	0.000203	0.000535	CcSEcCtD
Leflunomide—Insomnia—Risedronate—osteoporosis	0.000203	0.000535	CcSEcCtD
Leflunomide—Anxiety—Zoledronate—osteoporosis	0.000203	0.000534	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000202	0.000532	CcSEcCtD
Leflunomide—Paraesthesia—Risedronate—osteoporosis	0.000202	0.000531	CcSEcCtD
Leflunomide—Pruritus—Estropipate—osteoporosis	0.000201	0.000529	CcSEcCtD
Leflunomide—Discomfort—Zoledronate—osteoporosis	0.000201	0.000529	CcSEcCtD
Leflunomide—Asthenia—Alendronate—osteoporosis	0.000201	0.000529	CcSEcCtD
Leflunomide—Hypersensitivity—Ibandronate—osteoporosis	0.000201	0.000529	CcSEcCtD
Leflunomide—Cough—Conjugated Estrogens—osteoporosis	0.000201	0.000529	CcSEcCtD
Leflunomide—Dyspnoea—Risedronate—osteoporosis	0.0002	0.000527	CcSEcCtD
Leflunomide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.0002	0.0017	CbGpPWpGaD
Leflunomide—Erythema multiforme—Estradiol—osteoporosis	0.0002	0.000527	CcSEcCtD
Leflunomide—Hypotension—Pamidronate—osteoporosis	0.000199	0.000525	CcSEcCtD
Leflunomide—Dry mouth—Zoledronate—osteoporosis	0.000199	0.000524	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000199	0.000524	CcSEcCtD
Leflunomide—Fatigue—Ethinyl Estradiol—osteoporosis	0.000199	0.000523	CcSEcCtD
Leflunomide—Pruritus—Alendronate—osteoporosis	0.000198	0.000521	CcSEcCtD
Leflunomide—Dyspepsia—Risedronate—osteoporosis	0.000198	0.000521	CcSEcCtD
Leflunomide—Eye disorder—Estradiol—osteoporosis	0.000198	0.000521	CcSEcCtD
Leflunomide—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000198	0.00168	CbGpPWpGaD
Leflunomide—Constipation—Ethinyl Estradiol—osteoporosis	0.000197	0.000519	CcSEcCtD
Leflunomide—Hypersensitivity—Calcitriol—osteoporosis	0.000197	0.000518	CcSEcCtD
Leflunomide—Cardiac disorder—Estradiol—osteoporosis	0.000196	0.000517	CcSEcCtD
Leflunomide—Arthralgia—Conjugated Estrogens—osteoporosis	0.000196	0.000516	CcSEcCtD
Leflunomide—Chest pain—Conjugated Estrogens—osteoporosis	0.000196	0.000516	CcSEcCtD
Leflunomide—Myalgia—Conjugated Estrogens—osteoporosis	0.000196	0.000516	CcSEcCtD
Leflunomide—Asthenia—Ibandronate—osteoporosis	0.000195	0.000515	CcSEcCtD
Leflunomide—Anxiety—Conjugated Estrogens—osteoporosis	0.000195	0.000514	CcSEcCtD
Leflunomide—Nausea—Etidronic acid—osteoporosis	0.000195	0.000514	CcSEcCtD
Leflunomide—Anaphylactic shock—Zoledronate—osteoporosis	0.000195	0.000514	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000195	0.000512	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000194	0.000512	CcSEcCtD
Leflunomide—Diarrhoea—Estropipate—osteoporosis	0.000194	0.000512	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Risedronate—osteoporosis	0.000194	0.000511	CcSEcCtD
Leflunomide—Infection—Zoledronate—osteoporosis	0.000194	0.00051	CcSEcCtD
Leflunomide—Fatigue—Risedronate—osteoporosis	0.000194	0.00051	CcSEcCtD
Leflunomide—Insomnia—Pamidronate—osteoporosis	0.000193	0.000508	CcSEcCtD
Leflunomide—Pruritus—Ibandronate—osteoporosis	0.000193	0.000508	CcSEcCtD
Leflunomide—PTK2B—Immune System—IRAK3—osteoporosis	0.000192	0.00164	CbGpPWpGaD
Leflunomide—Constipation—Risedronate—osteoporosis	0.000192	0.000506	CcSEcCtD
Leflunomide—Pain—Risedronate—osteoporosis	0.000192	0.000506	CcSEcCtD
Leflunomide—CYP2C9—Biological oxidations—CYP27A1—osteoporosis	0.000192	0.00163	CbGpPWpGaD
Leflunomide—Paraesthesia—Pamidronate—osteoporosis	0.000192	0.000505	CcSEcCtD
Leflunomide—Diarrhoea—Alendronate—osteoporosis	0.000191	0.000504	CcSEcCtD
Leflunomide—Asthenia—Calcitriol—osteoporosis	0.000191	0.000504	CcSEcCtD
Leflunomide—Nervous system disorder—Zoledronate—osteoporosis	0.000191	0.000504	CcSEcCtD
Leflunomide—Immune system disorder—Estradiol—osteoporosis	0.000191	0.000503	CcSEcCtD
Leflunomide—Thrombocytopenia—Zoledronate—osteoporosis	0.000191	0.000503	CcSEcCtD
Leflunomide—Mediastinal disorder—Estradiol—osteoporosis	0.000191	0.000502	CcSEcCtD
Leflunomide—Dyspnoea—Pamidronate—osteoporosis	0.00019	0.000501	CcSEcCtD
Leflunomide—Tachycardia—Zoledronate—osteoporosis	0.00019	0.000501	CcSEcCtD
Leflunomide—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.00019	0.00161	CbGpPWpGaD
Leflunomide—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.00019	0.0005	CcSEcCtD
Leflunomide—Chills—Estradiol—osteoporosis	0.00019	0.0005	CcSEcCtD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—osteoporosis	0.000189	0.00161	CbGpPWpGaD
Leflunomide—Skin disorder—Zoledronate—osteoporosis	0.000189	0.000499	CcSEcCtD
Leflunomide—CYP2C9—Metapathway biotransformation—CYP27A1—osteoporosis	0.000189	0.00161	CbGpPWpGaD
Leflunomide—Pruritus—Calcitriol—osteoporosis	0.000189	0.000497	CcSEcCtD
Leflunomide—CYP1A2—Arachidonic acid metabolism—GPX1—osteoporosis	0.000189	0.0016	CbGpPWpGaD
Leflunomide—Hyperhidrosis—Zoledronate—osteoporosis	0.000188	0.000496	CcSEcCtD
Leflunomide—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000188	0.000496	CcSEcCtD
Leflunomide—PTK2B—TCR Signaling Pathway—IL6—osteoporosis	0.000188	0.0016	CbGpPWpGaD
Leflunomide—Diarrhoea—Raloxifene—osteoporosis	0.000188	0.000496	CcSEcCtD
Leflunomide—Dyspepsia—Pamidronate—osteoporosis	0.000188	0.000495	CcSEcCtD
Leflunomide—Dizziness—Estropipate—osteoporosis	0.000188	0.000495	CcSEcCtD
Leflunomide—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000188	0.000494	CcSEcCtD
Leflunomide—Alopecia—Estradiol—osteoporosis	0.000187	0.000492	CcSEcCtD
Leflunomide—Infection—Conjugated Estrogens—osteoporosis	0.000187	0.000491	CcSEcCtD
Leflunomide—Diarrhoea—Ibandronate—osteoporosis	0.000186	0.000491	CcSEcCtD
Leflunomide—Anorexia—Zoledronate—osteoporosis	0.000186	0.00049	CcSEcCtD
Leflunomide—Decreased appetite—Pamidronate—osteoporosis	0.000186	0.000489	CcSEcCtD
Leflunomide—Mental disorder—Estradiol—osteoporosis	0.000185	0.000488	CcSEcCtD
Leflunomide—Dizziness—Alendronate—osteoporosis	0.000185	0.000487	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000184	0.000485	CcSEcCtD
Leflunomide—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000184	0.000485	CcSEcCtD
Leflunomide—Malnutrition—Estradiol—osteoporosis	0.000184	0.000485	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—CALCR—osteoporosis	0.000184	0.00157	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PTH1R—osteoporosis	0.000184	0.00157	CbGpPWpGaD
Leflunomide—Fatigue—Pamidronate—osteoporosis	0.000184	0.000485	CcSEcCtD
Leflunomide—Gastrointestinal pain—Risedronate—osteoporosis	0.000184	0.000484	CcSEcCtD
Leflunomide—Tachycardia—Conjugated Estrogens—osteoporosis	0.000183	0.000483	CcSEcCtD
Leflunomide—Urticaria—Ethinyl Estradiol—osteoporosis	0.000183	0.000482	CcSEcCtD
Leflunomide—Constipation—Pamidronate—osteoporosis	0.000183	0.000481	CcSEcCtD
Leflunomide—Pain—Pamidronate—osteoporosis	0.000183	0.000481	CcSEcCtD
Leflunomide—Diarrhoea—Calcitriol—osteoporosis	0.000182	0.000481	CcSEcCtD
Leflunomide—Skin disorder—Conjugated Estrogens—osteoporosis	0.000182	0.00048	CcSEcCtD
Leflunomide—Hypotension—Zoledronate—osteoporosis	0.000182	0.00048	CcSEcCtD
Leflunomide—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000182	0.00048	CcSEcCtD
Leflunomide—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000182	0.00048	CcSEcCtD
Leflunomide—Dizziness—Raloxifene—osteoporosis	0.000182	0.000479	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IRS1—osteoporosis	0.000182	0.00154	CbGpPWpGaD
Leflunomide—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000182	0.000478	CcSEcCtD
Leflunomide—Flatulence—Estradiol—osteoporosis	0.000181	0.000478	CcSEcCtD
Leflunomide—Vomiting—Estropipate—osteoporosis	0.000181	0.000476	CcSEcCtD
Leflunomide—AHR—Circadian rythm related genes—IL6—osteoporosis	0.00018	0.00153	CbGpPWpGaD
Leflunomide—Dysgeusia—Estradiol—osteoporosis	0.00018	0.000475	CcSEcCtD
Leflunomide—Dizziness—Ibandronate—osteoporosis	0.00018	0.000475	CcSEcCtD
Leflunomide—Rash—Estropipate—osteoporosis	0.000179	0.000472	CcSEcCtD
Leflunomide—Dermatitis—Estropipate—osteoporosis	0.000179	0.000471	CcSEcCtD
Leflunomide—Anorexia—Conjugated Estrogens—osteoporosis	0.000179	0.000471	CcSEcCtD
Leflunomide—Urticaria—Risedronate—osteoporosis	0.000178	0.00047	CcSEcCtD
Leflunomide—Back pain—Estradiol—osteoporosis	0.000178	0.000469	CcSEcCtD
Leflunomide—Headache—Estropipate—osteoporosis	0.000178	0.000469	CcSEcCtD
Leflunomide—Vomiting—Alendronate—osteoporosis	0.000178	0.000469	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000178	0.000468	CcSEcCtD
Leflunomide—Abdominal pain—Risedronate—osteoporosis	0.000178	0.000468	CcSEcCtD
Leflunomide—Body temperature increased—Risedronate—osteoporosis	0.000178	0.000468	CcSEcCtD
Leflunomide—Muscle spasms—Estradiol—osteoporosis	0.000177	0.000466	CcSEcCtD
Leflunomide—Rash—Alendronate—osteoporosis	0.000176	0.000465	CcSEcCtD
Leflunomide—Insomnia—Zoledronate—osteoporosis	0.000176	0.000464	CcSEcCtD
Leflunomide—Dermatitis—Alendronate—osteoporosis	0.000176	0.000464	CcSEcCtD
Leflunomide—PTK2B—Immune System—ACTG1—osteoporosis	0.000176	0.0015	CbGpPWpGaD
Leflunomide—Feeling abnormal—Pamidronate—osteoporosis	0.000176	0.000463	CcSEcCtD
Leflunomide—Hypotension—Conjugated Estrogens—osteoporosis	0.000175	0.000462	CcSEcCtD
Leflunomide—Headache—Alendronate—osteoporosis	0.000175	0.000462	CcSEcCtD
Leflunomide—Paraesthesia—Zoledronate—osteoporosis	0.000175	0.000461	CcSEcCtD
Leflunomide—Vomiting—Raloxifene—osteoporosis	0.000175	0.000461	CcSEcCtD
Leflunomide—Gastrointestinal pain—Pamidronate—osteoporosis	0.000175	0.00046	CcSEcCtD
Leflunomide—Dyspnoea—Zoledronate—osteoporosis	0.000174	0.000458	CcSEcCtD
Leflunomide—Rash—Raloxifene—osteoporosis	0.000174	0.000457	CcSEcCtD
Leflunomide—Dermatitis—Raloxifene—osteoporosis	0.000173	0.000457	CcSEcCtD
Leflunomide—Vomiting—Ibandronate—osteoporosis	0.000173	0.000456	CcSEcCtD
Leflunomide—DHODH—Metabolism—ADCY5—osteoporosis	0.000172	0.00147	CbGpPWpGaD
Leflunomide—Headache—Raloxifene—osteoporosis	0.000172	0.000454	CcSEcCtD
Leflunomide—DHODH—Metabolism—GPX1—osteoporosis	0.000172	0.00146	CbGpPWpGaD
Leflunomide—Rash—Ibandronate—osteoporosis	0.000172	0.000452	CcSEcCtD
Leflunomide—Dermatitis—Ibandronate—osteoporosis	0.000172	0.000452	CcSEcCtD
Leflunomide—Dyspepsia—Zoledronate—osteoporosis	0.000172	0.000452	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000171	0.000451	CcSEcCtD
Leflunomide—Ill-defined disorder—Estradiol—osteoporosis	0.000171	0.00045	CcSEcCtD
Leflunomide—Headache—Ibandronate—osteoporosis	0.000171	0.00045	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL6R—osteoporosis	0.000171	0.00145	CbGpPWpGaD
Leflunomide—Insomnia—Conjugated Estrogens—osteoporosis	0.00017	0.000447	CcSEcCtD
Leflunomide—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.00017	0.000447	CcSEcCtD
Leflunomide—Vomiting—Calcitriol—osteoporosis	0.00017	0.000447	CcSEcCtD
Leflunomide—Decreased appetite—Zoledronate—osteoporosis	0.000169	0.000446	CcSEcCtD
Leflunomide—Nausea—Estropipate—osteoporosis	0.000169	0.000445	CcSEcCtD
Leflunomide—Body temperature increased—Pamidronate—osteoporosis	0.000169	0.000444	CcSEcCtD
Leflunomide—Abdominal pain—Pamidronate—osteoporosis	0.000169	0.000444	CcSEcCtD
Leflunomide—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000169	0.000444	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000168	0.000443	CcSEcCtD
Leflunomide—Angioedema—Estradiol—osteoporosis	0.000168	0.000443	CcSEcCtD
Leflunomide—Rash—Calcitriol—osteoporosis	0.000168	0.000443	CcSEcCtD
Leflunomide—Fatigue—Zoledronate—osteoporosis	0.000168	0.000443	CcSEcCtD
Leflunomide—Dermatitis—Calcitriol—osteoporosis	0.000168	0.000443	CcSEcCtD
Leflunomide—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000167	0.000441	CcSEcCtD
Leflunomide—Headache—Calcitriol—osteoporosis	0.000167	0.00044	CcSEcCtD
Leflunomide—Pain—Zoledronate—osteoporosis	0.000167	0.000439	CcSEcCtD
Leflunomide—Constipation—Zoledronate—osteoporosis	0.000167	0.000439	CcSEcCtD
Leflunomide—Nausea—Alendronate—osteoporosis	0.000166	0.000438	CcSEcCtD
Leflunomide—Malaise—Estradiol—osteoporosis	0.000166	0.000437	CcSEcCtD
Leflunomide—Hypersensitivity—Risedronate—osteoporosis	0.000165	0.000436	CcSEcCtD
Leflunomide—Vertigo—Estradiol—osteoporosis	0.000165	0.000436	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—osteoporosis	0.000165	0.00141	CbGpPWpGaD
Leflunomide—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000165	0.000435	CcSEcCtD
Leflunomide—Asthenia—Ethinyl Estradiol—osteoporosis	0.000165	0.000435	CcSEcCtD
Leflunomide—CYP1A2—Biological oxidations—CYP27A1—osteoporosis	0.000164	0.0014	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—IL6—osteoporosis	0.000164	0.00139	CbGpPWpGaD
Leflunomide—Nausea—Raloxifene—osteoporosis	0.000163	0.000431	CcSEcCtD
Leflunomide—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000163	0.00043	CcSEcCtD
Leflunomide—Pruritus—Ethinyl Estradiol—osteoporosis	0.000163	0.000429	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—IL6—osteoporosis	0.000163	0.00138	CbGpPWpGaD
Leflunomide—Palpitations—Estradiol—osteoporosis	0.000163	0.000429	CcSEcCtD
Leflunomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000162	0.00138	CbGpPWpGaD
Leflunomide—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000162	0.000427	CcSEcCtD
Leflunomide—Fatigue—Conjugated Estrogens—osteoporosis	0.000162	0.000426	CcSEcCtD
Leflunomide—Nausea—Ibandronate—osteoporosis	0.000162	0.000426	CcSEcCtD
Leflunomide—CYP1A2—Metapathway biotransformation—CYP27A1—osteoporosis	0.000162	0.00138	CbGpPWpGaD
Leflunomide—Asthenia—Risedronate—osteoporosis	0.000161	0.000424	CcSEcCtD
Leflunomide—Feeling abnormal—Zoledronate—osteoporosis	0.000161	0.000423	CcSEcCtD
Leflunomide—Cough—Estradiol—osteoporosis	0.000161	0.000423	CcSEcCtD
Leflunomide—Constipation—Conjugated Estrogens—osteoporosis	0.000161	0.000423	CcSEcCtD
Leflunomide—Pain—Conjugated Estrogens—osteoporosis	0.000161	0.000423	CcSEcCtD
Leflunomide—Gastrointestinal pain—Zoledronate—osteoporosis	0.000159	0.00042	CcSEcCtD
Leflunomide—Hypertension—Estradiol—osteoporosis	0.000159	0.000419	CcSEcCtD
Leflunomide—Pruritus—Risedronate—osteoporosis	0.000159	0.000418	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.000159	0.00135	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—MTHFR—osteoporosis	0.000159	0.00135	CbGpPWpGaD
Leflunomide—Nausea—Calcitriol—osteoporosis	0.000158	0.000417	CcSEcCtD
Leflunomide—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000158	0.000415	CcSEcCtD
Leflunomide—Hypersensitivity—Pamidronate—osteoporosis	0.000157	0.000414	CcSEcCtD
Leflunomide—Chest pain—Estradiol—osteoporosis	0.000157	0.000413	CcSEcCtD
Leflunomide—Myalgia—Estradiol—osteoporosis	0.000157	0.000413	CcSEcCtD
Leflunomide—Arthralgia—Estradiol—osteoporosis	0.000157	0.000413	CcSEcCtD
Leflunomide—Anxiety—Estradiol—osteoporosis	0.000156	0.000411	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000156	0.00041	CcSEcCtD
Leflunomide—Urticaria—Zoledronate—osteoporosis	0.000155	0.000408	CcSEcCtD
Leflunomide—Discomfort—Estradiol—osteoporosis	0.000155	0.000408	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—IL6—osteoporosis	0.000155	0.00132	CbGpPWpGaD
Leflunomide—Abdominal pain—Zoledronate—osteoporosis	0.000154	0.000406	CcSEcCtD
Leflunomide—Body temperature increased—Zoledronate—osteoporosis	0.000154	0.000406	CcSEcCtD
Leflunomide—Diarrhoea—Risedronate—osteoporosis	0.000154	0.000405	CcSEcCtD
Leflunomide—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000154	0.000404	CcSEcCtD
Leflunomide—Dry mouth—Estradiol—osteoporosis	0.000153	0.000404	CcSEcCtD
Leflunomide—Asthenia—Pamidronate—osteoporosis	0.000153	0.000403	CcSEcCtD
Leflunomide—Dizziness—Ethinyl Estradiol—osteoporosis	0.000152	0.000401	CcSEcCtD
Leflunomide—Pruritus—Pamidronate—osteoporosis	0.000151	0.000398	CcSEcCtD
Leflunomide—Anaphylactic shock—Estradiol—osteoporosis	0.00015	0.000396	CcSEcCtD
Leflunomide—Infection—Estradiol—osteoporosis	0.000149	0.000393	CcSEcCtD
Leflunomide—Urticaria—Conjugated Estrogens—osteoporosis	0.000149	0.000393	CcSEcCtD
Leflunomide—Dizziness—Risedronate—osteoporosis	0.000148	0.000391	CcSEcCtD
Leflunomide—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000148	0.000391	CcSEcCtD
Leflunomide—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000148	0.000391	CcSEcCtD
Leflunomide—Nervous system disorder—Estradiol—osteoporosis	0.000147	0.000388	CcSEcCtD
Leflunomide—PTK2B—Immune System—RAP1A—osteoporosis	0.000147	0.00125	CbGpPWpGaD
Leflunomide—Tachycardia—Estradiol—osteoporosis	0.000147	0.000386	CcSEcCtD
Leflunomide—Vomiting—Ethinyl Estradiol—osteoporosis	0.000146	0.000386	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—MGLL—osteoporosis	0.000146	0.00124	CbGpPWpGaD
Leflunomide—Diarrhoea—Pamidronate—osteoporosis	0.000146	0.000385	CcSEcCtD
Leflunomide—Skin disorder—Estradiol—osteoporosis	0.000146	0.000384	CcSEcCtD
Leflunomide—PTK2B—Immune System—CTSK—osteoporosis	0.000146	0.00124	CbGpPWpGaD
Leflunomide—Hyperhidrosis—Estradiol—osteoporosis	0.000145	0.000383	CcSEcCtD
Leflunomide—Rash—Ethinyl Estradiol—osteoporosis	0.000145	0.000382	CcSEcCtD
Leflunomide—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000145	0.000382	CcSEcCtD
Leflunomide—Headache—Ethinyl Estradiol—osteoporosis	0.000144	0.00038	CcSEcCtD
Leflunomide—Hypersensitivity—Zoledronate—osteoporosis	0.000144	0.000378	CcSEcCtD
Leflunomide—PTK2B—Immune System—NFATC1—osteoporosis	0.000143	0.00122	CbGpPWpGaD
Leflunomide—Vomiting—Risedronate—osteoporosis	0.000143	0.000376	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—LRP5—osteoporosis	0.000143	0.00121	CbGpPWpGaD
Leflunomide—Rash—Risedronate—osteoporosis	0.000142	0.000373	CcSEcCtD
Leflunomide—Dermatitis—Risedronate—osteoporosis	0.000141	0.000373	CcSEcCtD
Leflunomide—Dizziness—Pamidronate—osteoporosis	0.000141	0.000372	CcSEcCtD
Leflunomide—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000141	0.0012	CbGpPWpGaD
Leflunomide—Headache—Risedronate—osteoporosis	0.000141	0.000371	CcSEcCtD
Leflunomide—Asthenia—Zoledronate—osteoporosis	0.00014	0.000368	CcSEcCtD
Leflunomide—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000138	0.000364	CcSEcCtD
Leflunomide—Pruritus—Zoledronate—osteoporosis	0.000138	0.000363	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000137	0.000361	CcSEcCtD
Leflunomide—Nausea—Ethinyl Estradiol—osteoporosis	0.000137	0.00036	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—LRP6—osteoporosis	0.000137	0.00116	CbGpPWpGaD
Leflunomide—Insomnia—Estradiol—osteoporosis	0.000136	0.000358	CcSEcCtD
Leflunomide—Vomiting—Pamidronate—osteoporosis	0.000136	0.000357	CcSEcCtD
Leflunomide—Paraesthesia—Estradiol—osteoporosis	0.000135	0.000355	CcSEcCtD
Leflunomide—Asthenia—Conjugated Estrogens—osteoporosis	0.000135	0.000355	CcSEcCtD
Leflunomide—Rash—Pamidronate—osteoporosis	0.000135	0.000354	CcSEcCtD
Leflunomide—Dermatitis—Pamidronate—osteoporosis	0.000134	0.000354	CcSEcCtD
Leflunomide—Dyspnoea—Estradiol—osteoporosis	0.000134	0.000353	CcSEcCtD
Leflunomide—Headache—Pamidronate—osteoporosis	0.000134	0.000352	CcSEcCtD
Leflunomide—Diarrhoea—Zoledronate—osteoporosis	0.000133	0.000351	CcSEcCtD
Leflunomide—Nausea—Risedronate—osteoporosis	0.000133	0.000351	CcSEcCtD
Leflunomide—Pruritus—Conjugated Estrogens—osteoporosis	0.000133	0.00035	CcSEcCtD
Leflunomide—Dyspepsia—Estradiol—osteoporosis	0.000132	0.000348	CcSEcCtD
Leflunomide—Decreased appetite—Estradiol—osteoporosis	0.000131	0.000344	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Estradiol—osteoporosis	0.00013	0.000342	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL1B—osteoporosis	0.00013	0.0011	CbGpPWpGaD
Leflunomide—Fatigue—Estradiol—osteoporosis	0.00013	0.000341	CcSEcCtD
Leflunomide—Dizziness—Zoledronate—osteoporosis	0.000129	0.00034	CcSEcCtD
Leflunomide—Pain—Estradiol—osteoporosis	0.000128	0.000338	CcSEcCtD
Leflunomide—Constipation—Estradiol—osteoporosis	0.000128	0.000338	CcSEcCtD
Leflunomide—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000128	0.000338	CcSEcCtD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000128	0.00109	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—POMC—osteoporosis	0.000127	0.00108	CbGpPWpGaD
Leflunomide—Nausea—Pamidronate—osteoporosis	0.000127	0.000334	CcSEcCtD
Leflunomide—Dizziness—Conjugated Estrogens—osteoporosis	0.000124	0.000327	CcSEcCtD
Leflunomide—Vomiting—Zoledronate—osteoporosis	0.000124	0.000327	CcSEcCtD
Leflunomide—Feeling abnormal—Estradiol—osteoporosis	0.000124	0.000326	CcSEcCtD
Leflunomide—Rash—Zoledronate—osteoporosis	0.000123	0.000324	CcSEcCtD
Leflunomide—Gastrointestinal pain—Estradiol—osteoporosis	0.000123	0.000324	CcSEcCtD
Leflunomide—Dermatitis—Zoledronate—osteoporosis	0.000123	0.000323	CcSEcCtD
Leflunomide—Headache—Zoledronate—osteoporosis	0.000122	0.000322	CcSEcCtD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000122	0.00103	CbGpPWpGaD
Leflunomide—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.00012	0.00102	CbGpPWpGaD
Leflunomide—Vomiting—Conjugated Estrogens—osteoporosis	0.000119	0.000314	CcSEcCtD
Leflunomide—Urticaria—Estradiol—osteoporosis	0.000119	0.000314	CcSEcCtD
Leflunomide—Body temperature increased—Estradiol—osteoporosis	0.000119	0.000313	CcSEcCtD
Leflunomide—Abdominal pain—Estradiol—osteoporosis	0.000119	0.000313	CcSEcCtD
Leflunomide—Rash—Conjugated Estrogens—osteoporosis	0.000118	0.000312	CcSEcCtD
Leflunomide—Dermatitis—Conjugated Estrogens—osteoporosis	0.000118	0.000311	CcSEcCtD
Leflunomide—Headache—Conjugated Estrogens—osteoporosis	0.000118	0.00031	CcSEcCtD
Leflunomide—PTK2B—Immune System—PSMA2—osteoporosis	0.000117	0.000996	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PSMA5—osteoporosis	0.000117	0.000996	CbGpPWpGaD
Leflunomide—Nausea—Zoledronate—osteoporosis	0.000116	0.000305	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—TLN1—osteoporosis	0.000115	0.00098	CbGpPWpGaD
Leflunomide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.000114	0.00097	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PKM—osteoporosis	0.000113	0.000962	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—FDPS—osteoporosis	0.000113	0.000962	CbGpPWpGaD
Leflunomide—Nausea—Conjugated Estrogens—osteoporosis	0.000112	0.000294	CcSEcCtD
Leflunomide—Hypersensitivity—Estradiol—osteoporosis	0.000111	0.000292	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—osteoporosis	0.00011	0.000939	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.00011	0.000933	CbGpPWpGaD
Leflunomide—Asthenia—Estradiol—osteoporosis	0.000108	0.000284	CcSEcCtD
Leflunomide—ABCG2—Metabolism—PGLS—osteoporosis	0.000107	0.000912	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GPD2—osteoporosis	0.000107	0.000912	CbGpPWpGaD
Leflunomide—Pruritus—Estradiol—osteoporosis	0.000106	0.00028	CcSEcCtD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000104	0.000884	CbGpPWpGaD
Leflunomide—Diarrhoea—Estradiol—osteoporosis	0.000103	0.000271	CcSEcCtD
Leflunomide—CYP2C9—Biological oxidations—CYP19A1—osteoporosis	0.000101	0.000858	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—CYP19A1—osteoporosis	9.95e-05	0.000846	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—P4HB—osteoporosis	9.94e-05	0.000845	CbGpPWpGaD
Leflunomide—Dizziness—Estradiol—osteoporosis	9.94e-05	0.000262	CcSEcCtD
Leflunomide—PTK2B—Immune System—KL—osteoporosis	9.91e-05	0.000843	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ATIC—osteoporosis	9.81e-05	0.000834	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PNP—osteoporosis	9.81e-05	0.000834	CbGpPWpGaD
Leflunomide—CYP1A2—Phase 1 - Functionalization of compounds—POMC—osteoporosis	9.75e-05	0.000829	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PTH—osteoporosis	9.67e-05	0.000822	CbGpPWpGaD
Leflunomide—Vomiting—Estradiol—osteoporosis	9.55e-05	0.000252	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—RAP1A—osteoporosis	9.5e-05	0.000808	CbGpPWpGaD
Leflunomide—Rash—Estradiol—osteoporosis	9.47e-05	0.00025	CcSEcCtD
Leflunomide—Dermatitis—Estradiol—osteoporosis	9.47e-05	0.000249	CcSEcCtD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	9.46e-05	0.000805	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CNR2—osteoporosis	9.42e-05	0.000801	CbGpPWpGaD
Leflunomide—Headache—Estradiol—osteoporosis	9.41e-05	0.000248	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—NFATC1—osteoporosis	9.27e-05	0.000788	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	9.22e-05	0.000784	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—DKK1—osteoporosis	9.2e-05	0.000782	CbGpPWpGaD
Leflunomide—Nausea—Estradiol—osteoporosis	8.93e-05	0.000235	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—WNT1—osteoporosis	8.86e-05	0.000753	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—FGA—osteoporosis	8.62e-05	0.000733	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—CYP19A1—osteoporosis	8.62e-05	0.000733	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—osteoporosis	8.6e-05	0.000731	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—osteoporosis	8.58e-05	0.000729	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—CYP19A1—osteoporosis	8.5e-05	0.000723	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—OXCT1—osteoporosis	8.34e-05	0.00071	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CA2—osteoporosis	8.34e-05	0.00071	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—MGLL—osteoporosis	8.13e-05	0.000691	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	8.09e-05	0.000688	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PTHLH—osteoporosis	8.01e-05	0.000681	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—BMP2—osteoporosis	8.01e-05	0.000681	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—osteoporosis	8.01e-05	0.000681	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—osteoporosis	8.01e-05	0.000681	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	7.88e-05	0.00067	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—FGB—osteoporosis	7.84e-05	0.000667	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—AGER—osteoporosis	7.79e-05	0.000662	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ADCY5—osteoporosis	7.76e-05	0.00066	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL6—osteoporosis	7.6e-05	0.000646	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PSMA5—osteoporosis	7.57e-05	0.000644	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PSMA2—osteoporosis	7.57e-05	0.000644	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	7.37e-05	0.000627	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CALCA—osteoporosis	7.06e-05	0.0006	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—IDH2—osteoporosis	6.91e-05	0.000588	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IRS2—osteoporosis	6.79e-05	0.000577	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP27A1—osteoporosis	6.5e-05	0.000553	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KL—osteoporosis	6.41e-05	0.000545	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ACP5—osteoporosis	6.32e-05	0.000538	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	6.3e-05	0.000536	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	6.27e-05	0.000533	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—POMC—osteoporosis	6.06e-05	0.000515	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ADCY5—osteoporosis	5.96e-05	0.000507	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IRS1—osteoporosis	5.93e-05	0.000504	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—TPI1—osteoporosis	5.88e-05	0.0005	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—FDPS—osteoporosis	5.72e-05	0.000486	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PKM—osteoporosis	5.72e-05	0.000486	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL6R—osteoporosis	5.57e-05	0.000474	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—P4HB—osteoporosis	5.53e-05	0.00047	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GAPDH—osteoporosis	5.43e-05	0.000461	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PGLS—osteoporosis	5.42e-05	0.000461	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GPD2—osteoporosis	5.42e-05	0.000461	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	5.36e-05	0.000455	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—RAP1A—osteoporosis	5.28e-05	0.000449	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—POMC—osteoporosis	5.18e-05	0.00044	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ADCY5—osteoporosis	5.02e-05	0.000427	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ATIC—osteoporosis	4.96e-05	0.000421	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PNP—osteoporosis	4.96e-05	0.000421	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—FDPS—osteoporosis	4.89e-05	0.000415	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PKM—osteoporosis	4.89e-05	0.000415	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SPP1—osteoporosis	4.86e-05	0.000413	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GPD2—osteoporosis	4.63e-05	0.000394	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PGLS—osteoporosis	4.63e-05	0.000394	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IRS2—osteoporosis	4.39e-05	0.000373	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—LEP—osteoporosis	4.3e-05	0.000365	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ENO1—osteoporosis	4.27e-05	0.000363	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL1B—osteoporosis	4.24e-05	0.00036	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PNP—osteoporosis	4.24e-05	0.00036	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ATIC—osteoporosis	4.24e-05	0.00036	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—OXCT1—osteoporosis	4.21e-05	0.000358	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CA2—osteoporosis	4.21e-05	0.000358	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PSMA2—osteoporosis	4.21e-05	0.000358	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PSMA5—osteoporosis	4.21e-05	0.000358	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—MGLL—osteoporosis	4.11e-05	0.000349	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ESR1—osteoporosis	4.1e-05	0.000349	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	3.87e-05	0.000329	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IRS1—osteoporosis	3.83e-05	0.000326	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—POMC—osteoporosis	3.69e-05	0.000314	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—OXCT1—osteoporosis	3.6e-05	0.000306	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CA2—osteoporosis	3.6e-05	0.000306	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL6R—osteoporosis	3.6e-05	0.000306	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IGF1—osteoporosis	3.55e-05	0.000302	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—MGLL—osteoporosis	3.51e-05	0.000298	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—IDH2—osteoporosis	3.49e-05	0.000297	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP19A1—osteoporosis	3.41e-05	0.00029	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	3.31e-05	0.000281	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP27A1—osteoporosis	3.28e-05	0.000279	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ACP5—osteoporosis	3.19e-05	0.000272	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	3.15e-05	0.000268	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—IDH2—osteoporosis	2.98e-05	0.000254	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—TPI1—osteoporosis	2.97e-05	0.000252	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP27A1—osteoporosis	2.81e-05	0.000239	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—P4HB—osteoporosis	2.79e-05	0.000237	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ADCY5—osteoporosis	2.79e-05	0.000237	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GPX1—osteoporosis	2.78e-05	0.000236	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GAPDH—osteoporosis	2.74e-05	0.000233	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ACP5—osteoporosis	2.73e-05	0.000232	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	2.69e-05	0.000229	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—RAP1A—osteoporosis	2.67e-05	0.000227	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—MTHFR—osteoporosis	2.57e-05	0.000218	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—TPI1—osteoporosis	2.54e-05	0.000216	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL6—osteoporosis	2.48e-05	0.000211	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—P4HB—osteoporosis	2.39e-05	0.000203	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GAPDH—osteoporosis	2.34e-05	0.000199	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.33e-05	0.000198	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—RAP1A—osteoporosis	2.28e-05	0.000194	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ENO1—osteoporosis	2.16e-05	0.000183	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MYC—osteoporosis	2.13e-05	0.000181	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TGFB1—osteoporosis	2.13e-05	0.000181	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PSMA2—osteoporosis	2.13e-05	0.000181	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PSMA5—osteoporosis	2.13e-05	0.000181	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—POMC—osteoporosis	2.05e-05	0.000175	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.99e-05	0.000169	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ENO1—osteoporosis	1.84e-05	0.000157	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PSMA2—osteoporosis	1.82e-05	0.000154	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PSMA5—osteoporosis	1.82e-05	0.000154	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP19A1—osteoporosis	1.72e-05	0.000147	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL6—osteoporosis	1.6e-05	0.000136	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP19A1—osteoporosis	1.47e-05	0.000125	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ADCY5—osteoporosis	1.41e-05	0.00012	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GPX1—osteoporosis	1.4e-05	0.000119	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—MTHFR—osteoporosis	1.3e-05	0.00011	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ADCY5—osteoporosis	1.2e-05	0.000102	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GPX1—osteoporosis	1.2e-05	0.000102	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—MTHFR—osteoporosis	1.11e-05	9.42e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—POMC—osteoporosis	1.04e-05	8.81e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—POMC—osteoporosis	8.86e-06	7.53e-05	CbGpPWpGaD
